| Dr David Thomas Francois, MD | |
|
292 Saint Charles Way, York, PA 17402 | |
| (717) 851-6236 | |
| (717) 851-6243 |
| Full Name | Dr David Thomas Francois |
|---|---|
| Gender | Male |
| Speciality | Internal Medicine - Rheumatology |
| Location | 292 Saint Charles Way, York, Pennsylvania |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1083643373 | NPI | - | NPPES |
| 001451614 | Medicaid | PA | |
| 5683113 | Other | PA | AETNA |
| 50065231 | Other | PA | CAPITAL BLUE CROSS-WMG |
| 1142803 | Other | PA | AMERIHEALTH MERCY-WMG |
| 342741 | Other | PA | MAMSI-WMG |
| 543950 | Other | MD | CAREFIRST MD BCBS |
| 030077 | Other | PA | JOHNS HOPKINS |
| 38788 | Other | PA | GEISINGER |
| 1519847 | Other | PA | GATEWAY-WMG |
| 754618 | Other | PA | HIGHMARK BLUE SHIELD |
| 81773 | Other | PA | UNISON-WMG |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207R00000X | Internal Medicine | MD051965L (Pennsylvania) | Secondary |
| 207RR0500X | Internal Medicine - Rheumatology | MD051965L (Pennsylvania) | Primary |
| Entity Name | Wellspan Medical Group |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1750480299 PECOS PAC ID: 1951213115 Enrollment ID: O20040220000815 |
News Archive
VigiLanz Corporation has entered into contracts with Orlando Health, Inc., a group of seven hospitals in Orlando, Florida; and Contra Costa Regional Medical Center in Martinez, California, to license the VigiLanz product suite, consisting of the Dynamic PharmacoVigilance® (DPV) system, the Dynamic PracticeGuidance™ (DPG) system, and the VigiLanz Infection Control Monitor™ (ICM).
Tourette's syndrome is characterised by tics caused in many by premonitory urges; sensations which give patients compulsion to act to relieve discomfort. Habit reversal therapy conditions patients into heightened awareness of premonitory urges and forced counteraction of the tic.
The Bill & Melinda Gates Foundation and China's Ministry of Science and Technology (MOST) on Wednesday signed a Memorandum of Understanding to form a partnership to support new research and development (R&D) and production of new products for global health and agriculture, Agence France-Presse reports.
Clovis Oncology, Inc. announced today that the first clinical study of CO-1686 has commenced with the dosing of the first patient at a U.S. study site. CO-1686 is a novel, oral, targeted covalent inhibitor of epidermal growth factor receptor (EGFR) mutations currently being studied for the treatment of non-small cell lung cancer.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr David Thomas Francois, MD 1803 Mount Rose Ave, Suite B3, York, PA 17403-3026 Ph: (717) 851-1405 | Dr David Thomas Francois, MD 292 Saint Charles Way, York, PA 17402 Ph: (717) 851-6236 |
News Archive
VigiLanz Corporation has entered into contracts with Orlando Health, Inc., a group of seven hospitals in Orlando, Florida; and Contra Costa Regional Medical Center in Martinez, California, to license the VigiLanz product suite, consisting of the Dynamic PharmacoVigilance® (DPV) system, the Dynamic PracticeGuidance™ (DPG) system, and the VigiLanz Infection Control Monitor™ (ICM).
Tourette's syndrome is characterised by tics caused in many by premonitory urges; sensations which give patients compulsion to act to relieve discomfort. Habit reversal therapy conditions patients into heightened awareness of premonitory urges and forced counteraction of the tic.
The Bill & Melinda Gates Foundation and China's Ministry of Science and Technology (MOST) on Wednesday signed a Memorandum of Understanding to form a partnership to support new research and development (R&D) and production of new products for global health and agriculture, Agence France-Presse reports.
Clovis Oncology, Inc. announced today that the first clinical study of CO-1686 has commenced with the dosing of the first patient at a U.S. study site. CO-1686 is a novel, oral, targeted covalent inhibitor of epidermal growth factor receptor (EGFR) mutations currently being studied for the treatment of non-small cell lung cancer.
› Verified 7 days ago
Robert A Fritz, DO Rheumatology Medicare: Not Enrolled in Medicare Practice Location: 1777 5th Ave, York, PA 17403 Phone: 717-843-8051 Fax: 717-846-0721 | |
Dr. Aruna Chelliah, MD Rheumatology Medicare: Not Enrolled in Medicare Practice Location: 292 Saint Charles Way, York, PA 17402 Phone: 717-851-6231 Fax: 717-741-1719 | |
Ali Abbas, MD Rheumatology Medicare: Accepting Medicare Assignments Practice Location: 2690 Southfield Dr Ste A, York, PA 17403 Phone: 717-741-1414 Fax: 717-741-4774 | |
Amna Chaudary, MD Rheumatology Medicare: Medicare Enrolled Practice Location: 1001 S George St, York, PA 17403 Phone: 717-741-8003 Fax: 717-741-8016 | |
Dr. Iain Lewis Mackenzie, M.D. Rheumatology Medicare: Not Enrolled in Medicare Practice Location: 25 Monument Road Suite 250, Apple Hill Medical Center Digestive Disease Center, York, PA 17403 Phone: 717-741-9344 Fax: 717-741-9633 | |
Johat Aponte, MD Rheumatology Medicare: Accepting Medicare Assignments Practice Location: 1701 Innovation Dr, York, PA 17408 Phone: 717-843-8623 Fax: 717-815-2489 | |
Manuel Jose Rovira Gonzalez, Rheumatology Medicare: Medicare Enrolled Practice Location: 1001 S George St, York, PA 17403 Phone: 717-741-8003 Fax: 717-741-8016 |